Title of Invention	A COMPOSITION FOR AFFECTING CHANGES IN MAMMALIAN HAIR GROWTH, HAIR PIGMENTATION AND HAIR SHAFT AND FOLLICLE SIZE.
Abstract	The present invention utilizes natural and/or synthetic serine pros ease imhibitory agents or botanical extracts containing serine pros ease inhibitory activity, with or without the addition of one or more isoflavones and/or additional natural extracts containing one or more isoflavones, and their ability to affect changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation. (FIG.)nil

Title of Invention

A COMPOSITION FOR AFFECTING CHANGES IN MAMMALIAN HAIR GROWTH, HAIR PIGMENTATION AND HAIR SHAFT AND FOLLICLE SIZE.

Abstract

The present invention utilizes natural and/or synthetic serine pros ease imhibitory agents or botanical extracts containing serine pros ease inhibitory activity, with or without the addition of one or more isoflavones and/or additional natural extracts containing one or more isoflavones, and their ability to affect changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation. (FIG.)nil

Full Text	REDUCING HAIR GROWTH, HAIR FOLLICLE AND HAIR SHAFT SIZE AND HAIR PIGMENTATION Miri Seiberg, Stanley Shapiro, Jue-Chen Liu, Jonathan Miller Field of the Invention This invention is related to methods and compositions effective for reducing hair growth. More specifically, the present invention is directed to methods for changing the rate of hair growth, reducing the size of the hair follicle and the hair shaft, and reducing hair shaft pigmentation, by topical application of either botanical extracts containing serine protease inhibitory activity and in particular soybean extracts such as soymilk, or mixtures and formulations of the above, combined with other active ingredients such as isoflavones. Background of the Invention One main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed essentially for social and cosmetic purposes. Many procedures are used to remove unwanted hair including shaving, electrolysis, plucking, laser and light therapies and injection of therapeutic antiandrogens. These conventional methods are not without their shortcomings. Shaving, for instance, may result in nicks and cuts in the skin"s surface, may leave a perception of an increase in the rate of hair regrowth, and may also leave undesirable stubble. While electrolysis may keep an area free of unwanted hair for a prolonged period of time, the process is often expensive and painful and may further result in scarring. Not only may plucking cause pain and discomfort, but it often result in a poor removal of short hair. Several unwanted side effects, such as effects on muscularity, often accompany the use of antiandrogens. For these reasons, better methods for reducing hair growth are needed. Pseudofolliculitis barbae is an inflammatory hair disorder, most commonly found on the beard area. Inflammatory follicular papules result when hair tips penetrate into the skin rather than passing through the follicular orifice. This process is extremely common in black men because their hairs are frequently curly, exiting the skin at an acute angle. Close shaves, particularly with a razor blade, predispose them to pseudofolliculitis barbae. The most effective treatment available is to allow the hairs to grow well beyond the skin surface. Such a treatment is often not desired. Hirsutism is a relatively frequent condition affecting about 4% of women. Facial hirsutism often interferes with personal and work activities, and temporary hair removal is a major component in the management of hirsute patients. Shaving is the most frequently used temporary method for facial hair, as plucking, waxing and depilatories are more difficult to tolerate and care must be taken to avoid folliculitis, pigmentation, and scarring. Cosmetic cover-ups are usually used to hide cuts and stubble and electrolysis and thermolysis may be used for permanent hair removal when affordable. An alternative or complementary desired approach to hair removal, would be a method to reduce hair growth, reduce hair follicle and hair shaft size and reduce hair shaft pigmentation. Such an approach could reduce the visibility of existing hair, making it softer and lighter. When combined with other methods of hair removal such a method could enhance and prolong the removal effect, and reduce the need and frequency of hair removal. Long term use of such an approach could lead to attenuated, soft, pigmentation-reduced hair growth, that is less visible and does not require the use of other removal methods. Reduced hair growth is desired in the axilla area (fossa axillaris), where deodorants and anti-perspirants are used to control odor trapped within the axillary hairs. It would be desired to have products for under- arm use, which combine deodorant or anti-perspirant activities with reduced hair growth activity. African type hair is unique in its morphology -- a kinky hair shaft with variations in diameter. This complex shaft structure creates the need for specialized grooming products and procedures to ensure that the African type hair maintains cosmetic desired properties. It is desired to have products that reduce this complexity and make the African type hair more manageable, improving its appearance. It would be desirable to provide a method for chemically or naturally affecting hair growth, hair follicle and hair shaft size and hair shaft pigmentation, which does not cause unwanted side effects to the user. Summary of the Invention In accordance with the present invention, we have found compositions and methods for affecting changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation by topically applying to the skin of a mammal an effective amount of a topically active composition comprising protease inhibitors, botanical extracts, and in particular legume extracts including, but not limited to, soymilk, for a period of time sufficient to affect hair growth, hair follicle and hair shaft size and hair shaft pigmentation. Such topically active compositions may be further combined with other active ingredients including, but not limited to, synthetic or naturally- occurring isoflavones, to enhance the desired effects on hair growth and pigmentation. The compositions and methods of this invention provide a unique, convenient means for delaying hair growth, reducing hair follicle and hair shaft size and hair shaft pigmentation, by using serine protease inhibitors, botanical extracts of the legume family, and in particular, but not limited to, soymilk, containing serine protease inhibitory activity, and their combinations with isoflavones. Brief Description of the Drawings The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing (s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which: Figure 1: A photograph of control and soymilk treated C57B1/6 mouse hair (high magnification). Figure 2: Histological sections of control and soymilk- treated C57B1/6 mouse hair follicles at day four of the hair cycle. Figure 3: Histological sections of control and soymilk- treated C57B1/6 mouse hair follicles at day seven of the hair cycle, high and low magnifications. Figure 4: Histological sections of control and soymilk- treated C57B1/6 mouse hair follicles at day 18 of the hair cycle. Figure 5: Histological sections of control and soymilk- treated C57B1/6 mouse hair follicles at day 21 of the hair cycle. Figure 6: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (High magnification) at day seven of the hair cycle. Figure 7: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (lower magnifications) at day seven of the hair cycle. Figure 8: Histological sections of control and soymilk- treated C3H mouse hair follicles at day 21 of the hair cycle. Figure 9: A photograph of control and soymilk-derived proteins treated C3H mouse hair (high magnification). Figure 10: Histological sections of control and soymilk- derived proteins-treated C57B1/6 mouse hair follicles (High magnification) at day eight of the hair cycle. Figure 11: A graph demonstrating the trypsin inhibitory activity of soymilk. Figure 12: Western blot of C57B1/6 mouse skins throughout the hair cycle, demonstrating reduced tyrosinase and TRP-1 protein levels following soymilk treatment. Figure 13: Photographs of untreated and soymilk treated sides of human face, treated with soymilk daily for four weeks. Figure 14: Quantitative analysis of hair follicle dimensions with and without soymilk treatment. Figure 15: Photographs of human leg hair following five weeks of soymilk treatment on one leg. Figure 16: Photographs of control, soymilk, and isoflavone-enriched soymilk treated C57B1/6 mouse hair (high magnification). Figure 17: Histological sections of control, soymilk, and isoflavone-enriched soymilk treated C57B1/6 mouse skins at day 15 of the hair cycle, documenting the thickness and color of the hair shafts. Figure 18: Photograph of C57B1/6 mouse hair after three weeks of treatment with various soymilk and isoflavones formulations. Detailed Description of Preferred Embodiments As used herein, "mammal" shall mean any member "of the higher vertebrate animals comprising the class Mammalia," as defined in Webster"s Medical Desk Dictionary 407 (1986) , and includes but is not limited to humans. As used herein "(%, w/v)" shall mean grams of a given component per 100 ml of the total composition. Topically active agents suitable for use in the composition of the present invention include protease inhibitors and natural plant extracts having protease inhibitory activity and mixtures thereof. Preferred protease inhibitors are serine protease inhibitors, and in particular Soybean Trypsin Inhibitor ("STI") and the soybean-derived Bowman Birk Inhibitor ("BBI). Preferred botanical extracts are of the legume family and in particular bean extracts, such as soymilk. Preferably, the protease inhibitors are present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 20% (w/v), and more preferably from about 0.001% (w/v) to about 5% (w/v). Preferably, botanical aqueous extracts such as soymilk are present in an amount of 10-99% (v/v), and more preferably from 50-99% (v/v). We have unexpectedly found that when topically active agents such as described above, and in particular soymilk or soymilk containing formulations, are enriched with isoflavones, and in particular soybean-derived isoflavones, the inhibitory effect on hair growth, hair dimensions and hair pigmentation is enhanced. Preferably, the isoflavones are present in the botanical aqueous extracts such as soymilk in an amount of 0.000005-15% (v/v), and more preferably from 0.00001-10% (v/v) . If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition of the present invention may be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the hair follicle and the skin. The pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof. These will be combined in an amount which will not affect the serine protease inhibitory activity, in order to produce cosmetic or pharmaceutical products such as, non- exclusively, essences, creams, lotions, pastes, gels, powders, patches or injectables and the like for the reduction of hair growth, hair size and hair pigmentation. The compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect. For example, the compositions of this invention may be applied in conjunction with one or more products whose purpose is to facilitate the removal of hair to to actually remove hair, reduce hair visibility, improve hair style or improve hair management. The compositions of this invention may be applied topically prior to, during or following hair removal. They may be applied topically concurrently with one or more of the following group: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask or bath additives. The compositions of this invention may be applied daily for at least four to eight weeks, by which an effect upon the appearance of hair should be observed. Application may be continued as long as desired to maintain the condition of the hair. Daily application to the face may mitigate the condition of pseudofolliculitis barbae and/or hirsutism; application to the axillary area may reduce hair growth under the arms and application to the scalp and hair may assist in managing and styling African-type hair. The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect changes in mammalian hair growth, hair follicle and hair shaft size and hair shaft pigmentation. As used herein "amount effective" shall mean an amount sufficient to cover the region of skin surface where a delay in hair growth and hair pigmentation and reduced hair size are desired. Preferably, the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 µl /cm2 to about 500 µl /cm2 of topically active agent is present when a delay in hair growth, hair size and hair pigmentation is desired. We have unexpectedly found that when topically active agents, such as soymilk, or isoflavone-enriched soymilk are topically applied to an animal"s skin, a significant delay in hair growth, hair follicle and hair shaft size and hair shaft pigmentation was achieved. We further believe that since the hair growth cycle for humans is often slower than that for mice, it is further likely that the hair growth delay in humans would be considerably longer than in mice. The invention illustratively disclosed herein suitably might be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof. Examples EXAMPLE 1; Depilation of Test Subjects in the Mouse System C57BI/6 or C3H mice (male and female) were obtained from Charles River (Kingston, NY) , at 8 -10 weeks of age and were in the resting (telogen) phase of their respective hair cycle. Hair growth was induced by wax depilation (plucking) of each respective animal"s back fur according to the procedure set forth in Stenn, et al., "Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration," 6 Skin Pharmacol. , 125 -134 (1993). In C57B1/6 and C3H mice, 8-10 weeks old, the growth phase (anagen) starts synchronously in all hair follicles at the time of depilation. As illustrated in Table 1, the following observations were noticed at the induction site: As shown in Table 1, the hair growth was visible several days after depilation as the pink skin of the animal began to darken. This is likely due to hair pigmentation in the shaft since the C57BI/6 and C3H mice contained melanocytes only in the hair follicles and not in the dorsal epidermis. Similar hair growth pattern was documented in our international application No. PCT/US 97/11033, when chemical depilation using commercially available products was performed. Since the murine hair cycle varies not only between strains, but also amongst individual animals, the status of the hair cycle was analyzed in each animal on study. A 2 cm by 1 cm skin sample was isolated from each mouse with scissors, fixed with a 10% buffered formalin solution having a pH of about 6.9 - 7.1 at 25 °C (Stephens Scientific), and then formed into a paraffin block according to well-known procedures. The block was then microtomed, and sections were stained with H&E or Fontana-Mason stain. Sections were examined histologically in order to verify the phase of the hair cycle, the size of the hair follicle and hair shaft and the level of hair pigmentation, using procedures well known in the art. Hair length was assessed visually, and by using a low magnification (x8) dissecting microscope. This Example, as well as the one described in our international application No. PCT/US 97/11033, shows that the hair growth cycle for C57BI/6 and C3H mice averaged about 25 days and reports similar timing of hair follicle and shaft development regardless of the method used for depilation. EXAMPLE 2; Preparation of soymilk and sovmilk formulations One way to make soymilk is to soak the soybeans in deionized or purified water for several hours, and grind them after they were fully hydrated, with the addition of small quantities of water. (The grinding process allows the soybean milk to be extracted). After collection, the soybean milk may be filtered to remove any residual parts of the bean husk. The soymilk used in the formulations described below can be fresh soymilk as described above, or may be made from soybean powder and water. The soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze- dried and the resulting soymilk may or may not be filtered. Such prepared soymilk may have from about 1 to about 90% by weight dry soybean powder. Another example is the use of soymilk powder, made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization. Other methods of soybean extraction could also be used to create the active ingredients in the formulations described below. For example, the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the serine protease inhibitory activity of the soybean will be retained, and preferably that the protein STI will remain intact. The soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. For example, but not limiting to, soybean strains particularly rich in its Soybean Trypsin Inhibitor (STI) content or in isoflavone content, or growth conditions that result in STI or isoflavone enrichment in the bean, might be preferred. It should be noted that the soy products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others. If necessary, the odor of the compositions of this invention may be reduced by using soybean products derived from specific strains of soybeans known to produce reduced-odor, including, but not limited to, lipoxygenase-2-deficient beans and those having modified sugar profile, and the like. A process to reduce oxygen levels in the formulation may also reduce the odor. Various masking agents or fragrances may also be used to mask the odor. The compositions of this invention may further comprise surfactants, moisturizers, humectants, conditioners, fragrances, colorants, preservatives, anti-oxidants, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, foaming agents, cosmetic adjuvants, buffering agents or mixtures thereof. The compositions of this invention may be left on the skin for a period sufficient to effect changes. For example, the compositions of this invention may be applied to the skin daily treatment for at least about four weeks, more preferably, the composition should applied daily for at least eight weeks. Another method according to this invention is a method to reduce or prevent pseudofolliculitis barbae. Daily application of the compositions of this i nvention may reduce or prevent this condition. The compositions of this invention may also be applied daily to the axilliary area to reduce hair growth. Furthermore, the compositions of this invention may be applied daily to the scalp to style and improve management of African type hair. As shown in our co-pending U.S. Patent Application (Attorney Docket No. JBP 430), numerous soymilk-based formulations could be used to reduce pigmentation. All these formulations could also be used to reduce hair growth. Some particularly preferred examples of soymilk formulations and soymilk formulations containing isoflavones are shown in table 2 below. An example for an isoflavones preparation that could be used in this invention is Flavosterone SE from Ichimaru, Japan, which contains about 0.1% pure isoflavones. In all these formulations, soymilk could be replaced with the appropriate quantities of soybean powder or soymilk powder and water. EXAMPLE 3: Preparation of Topically Active Compositions containing soybean derived protease inhibitors Soybean trypsin inhibitor (STI) and Bowman-Birk inhibitor (BBI), from Sigma-Aldrich Corporation were mixed into a 0.1M phosphate buffered saline (PBS, Gibco- BRL, Gaithersburg, MA), pH 7.4, in concentrations of 1% to 0.001% (w/v) . Four volumes of the resulting solutions were then mixed with 1 volume of (100 mg/ml) liposomes vehicle, which was prepared by the methods described in Niemiec et. al, in order to yield the topically active composition. Non-ionic liposomes preparations, such as those disclosed in Niemiec et al., "Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model," 12 Pharm. Res. 1184-88 (1995) ("Niemiec"), which is incorporated by reference herein in its entirety, are well known in the art, and are described our U.S. Patent Application (Attorney Docket No. JBP 430) . GDL liposomes were prepared as set forth in Niemiec, et al., above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M, pH 7.4 (Gibco-BRL of Gaithersburg, MD) were used as the aqueous phase in the preparation of the liposomes. EXAMPLE 4; Soymilk Delays Hair Growth and reduce hair follicle and hair shaft size and Hair shaft Pigmentation C57B1/6 mice were induced for a new hair cycle as described in Example 1, and treated daily with soymilk. Animals were observed daily for their hair growth pattern, and skin biopsies were taken at important time points of the hair cycle. As a result of soymilk treatment the hair growth of the treated mice was delayed, and their hairs were visibly thinner, and smoother to touch. Treated mice did not show skin darkness at days 7-8 of the hair cycle, as expected, and hair shafts were not visible at days 11-12 as in the control animals. In average, the hair cycle of the soymilk treated mice was delayed by 3-6 days. Figure 1 is a picture of the mice fur, showing the difference in hair appearance, color, size and thickness following soymilk treatment. Histological examination of the biopsied skin samples confirmed these observations. As shown in Figure 2 by Fontana-Mason (F&M) staining, at day four of the hair cycle the untreated hair follicle is fully developed, as expected, containing all the cellular layers and pigment deposition. In contrast, the soymilk treated sample, (shown at same magnification), shows a smaller and not as fully developed hair follicle, with no pigment deposition. Figure 3 shows two sets of histological sections stained with F&M, of lower and higher magnification. These sections are from day seven of the hair cycle. The upper panel shows that soymilk treated skin has smaller, shorter, and less pigmented hair follicles than the untreated control. The lower panel shows a higher magnification of the follicles, further demonstrating the difference in hair follicle and hair shaft size and pigmentation following soymilk treatment. Figure 4 shows low magnification of F&M stained skin sections at day 18 of the hair cycle. At this magnification it is obvious that soymilk treatment results in reduced hair follicle size, which leads to reduced hair shaft length and thickness, and reduced total pigment deposition within the treated follicles. Figure 5 shows skin sections at day 21 of the hair cycle, with two magnifications. The upper panel demonstrates that the control animals were in the catagen stage, when hair follicles are regressing. Soymilk treated follicles, on the other hand, had already completed the catagen stage, as they are shown in telogen, the resting stage. This indicates that not only the hair cycle was delayed following soymilk treatment, it was also prematurely terminated. The lower panel demonstrates the catagen control follicle and the shorter, telogen (resting) soymilk-treated follicle using higher magnification. EXAMPLE 5; The effects of soymilk on hair growth, size and pigmentation are reproducible in C3H mice In order to verify that the effect of soymilk on hair growth is not specific to C57B1/6 mice, we repeated the experiment described in Example 4 using the brown haired (Agouti) C3H mice. The results of these experiments were similar both visually and histologically. Soymilk delayed hair growth and reduced hair follicle and hair shaft size and pigment deposition in the C3H mice. Histological analysis confirmed these visual observations. As shown in the upper panel of Figure 6, using F&M staining, at day seven of the hair cycle soymilk treated follicles are smaller and accumulate less pigment than untreated controls. The upper panel of Figure 7 (F&M staining) shows a lower magnification of the same skin sections, demonstrating the thinner and less pigmented follicles following soymilk treatment. Figure 8 shows F&M stained skin sections at day 21 of the hair cycle. As shown for the C57B1/6 mice, following soymilk treatment the hair cycle terminates prematurely. Soymilk treated follicles are in the resting state, while untreated control follicles are still in catagen. EXAMPLE 6; The effects of soymilk and soybean derived serine protease inhibitors on hair growth, size and pigmentation In search for a mechanism to explain the effect of soymilk on hair growth, we tested the effect of the soymilk-derived serine protease inhibitors, STI and BBI. We had shown earlier that these proteins induce depigmentation in skin, by affecting the PAR-2 pathway (U.S. Patent Application, Attorney Docket No. JBP 430) . The experiments described in Example 4 were repeated using STI, BBI, and soymilk. STI and BBI were used in a PBS-liposome vehicle as described in Example 3. Visual observations throughout the hair cycle confirmed that both STI and BBI could delay hair growth and reduce hair follicle and hair shaft size, similar to soymilk (see hair pictures in Figure 9) . Using high concentrations of STI or BBI, the effect on hair growth and pigmentation was substantial. Histological analysis confirmed these finding. As shown in Fig. 6, at day seven of the hair cycle 1% of STI and 1% of BBI reduce hair follicle and hair shaft size and hair shaft pigmentation in C3H mice. Figure 7 shows lower magnification sections of the same day into the hair cycle, demonstrating smaller hair follicles and hair shafts and reduced pigmentation, relative to untreated control, with soymilk, STI or BBI treatment. Figure 10 shows that STI and BBI have the same effect in C57B1/6 mice too, demonstrating smaller and less pigmented follicles. Taken together, this example shows that STI and BBI are soybean-derived serine protease inhibitors, found in soymilk, that could delay hair growth, reduce hair follicle and hair shaft size and reduce hair pigmentation. STI and BBI could represent a part of the soymilk ingredients that affects hair growth. In order to support the hypothesis that STI and BBI in soymilk are involved in the hair growth effects described above, we tested soymilk for its serine protease inhibitory activity. An enzymatic assay was performed using "Enzchek", a protease digestion fluorescent test system made by Molecular Probes of Eugene, OR. Using 100 units of trypsin (from Sigma chemicals, St. Louis MO) the test system produced fluorescence reading of about 1100 units. This reaction was inhibited with increasing concentrations of STI, as expected from a known trypsin inhibitor. Serial dilutions of soymilk were tested in this assay, and found to inhibit trypsin activity. As shown in Figure 11, soymilk exerts trypsin inhibitory activity similar to about 0.2% of pure STI. This suggests that soymilk could exert its hair growth effect, at least in part, by STI and BBI. EXAMPLE 7:___Soymilk Induces Chancres in Tyrosinase and TRP-1 protein expression The histological analyses of soymilk treated skin samples described in the examples above show dramatic reduction in pigment deposition within the hair follicle. To further understand the mechanism of soymilk-induced depigmentation, we studied tyrosinase, the key enzyme in melanogenesis and Tyrosinase-Related Protein-1 (TRP-1), the enzyme that stabilizes tyrosinase. C57B1/6 and C3H mice were treated as described above, and samples were collected throughout the study for protein analysis. Protein extraction and Western blot analysis were performed using standard procedures, such as the one described in Current Protocols in Cell Biology, Edited by Juan S. Bonifacino et al. Chapter 6: Electrophoresis and Immunoblotting. Copyright 1999 by John Wiley & Sons, Inc., which is incorporated herein by reference in its entirety. An example of one such study is shown in Figure 12. Equal amounts of skin-extracted proteins were probed with the anti-tyrosinase antibody "anti PEP1", and with the anti-TRP-1 antibody "anti PEP7" which are described in Jimenez, M., Kameyama, K., Maloy, WL, Tomita Y., and Hearing, V. Mammalian tyrosinase: biosynthesis, processing and modulation by melanocyte stimulating hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34, and Jimenez, M., K., Maloy, WL, and Hearing, V. Specific identification of an authentic tyrosinase clone. J. Biol. Chem. (1989) 264:3397-3403, which are incorporated herein by reference in their entirety. As shown in Figure 12, The expression of Tyrosinase and TRP-1 proteins is dramatically affected by soymilk treatment. Tyrosinase and TRP-1 levels are reduced, and the duration of the expression is shortened. These two factors affect overall hair pigmentation, which is reduced due to the reduced level and shorter duration of melanogenesis. EXAMPLE 8; Soymilk reduces human facial hair lenath and thickness An individual male with dark facial hair who shaves daily was treating the right side of his face with soymilk, immediately after shaving, for five weeks. By the third week, and more noticeably by the forth week, the hair of the treated side was visually lighter and felt smoother to touch. Digital pictures at different magnifications were taken throughout the treatment period, using Hi-Scope. These pictures clearly demonstrate the reduced size and thickness of the hair shafts at the treated side. An example of such pictures is shown in Figure 13, demonstrating the difference in hair shaft thickness and density at four weeks of treatment. Since both sides of the face were shaved at the same time, and pictures of both sides were taken at the same time, the difference in length of the facial hair indicates slower growth rate at the treated area. Figure 14 shows a computerized image analysis of the facial hair length, thickness and total area, following four weeks of soymilk treatment. All images were analyzed with Image Pro Plus 3.0 software (Media Cybernetics, Silver Spring, MD) . Data are presented as average of 180 hair shafts of each side of the face, with standard deviation (SigmaPlot® 5.0, SPSS Science, Chicago, IL) . Statistical analysis was performed using SigmaStat® 2.0 (SPSS Science) software, demonstrating a statistical significant difference in all measured parameters, following soymilk treatment. EXAMPLE 9; Soymilk reduces human legs hair length and thickness Hair was wax-depilated of two symmetrical areas of the medial part of the legs, below the knee, in one individual. One leg was treated daily, for four weeks, with soymilk. Visual observations indicate slower hair growth on the treated site. Hair shafts were reduced in number and were shorter and thinner than those of the untreated site, as shown in Figure 15. These observations further confirm the effect of soymilk on hair growth. Examples 8 and 9 together confirm that the effect of soymilk on human hair growth is not related to the method of hair removal or to the body part being treated. EXAMPLE 10:______Soymilk formulations enriched with isoflavones are preferred to soymilk formulations in reducing hair growth and pigmentation. The experiments described in Example 4 were repeated, using two formulations described in Table 2 above, Soymilk Essence 23 which is a soymilk-based formulation, and soymilk Essence 30 which is identical to Soymilk Essence 23 except the addition of 5% of a 0.1% isoflavones extract. As shown in Figure 16, mice treated with Soymilk essence 23 show reduced hair growth and nicer hair appearance. This effect was more pronounced with the use of soymilk Essence 30, demonstrating that isoflavone-enriched soymilk formulations are superior to soymilk formulations in reducing hair growth. Figure 17 shows histological skin sections of the treated mice, at day 15 of the treatment. The hair shafts documented in these sections clearly demonstrate the reduction in hair shaft dimensions, the reduced level of pigmentation within the hair shaft, and the increased smoothness of the hair shaft following the Soymilk Essence treatments. EXAMPLE 11;______Soymilk formulations enriched with isoflavonea are preferred to isoflavone formulations which are effective in reducing hair growth and pigmentation. The experiments described in Example 4 were repeated, using formulations described in Table 2 above, of soymilk essence with or without increasing concentrations of isoflavones. These Soy Essence formulations were compare to similar formulations, where the soymilk component only was replaced with water. These three sets of formulations (Soy Essence, isoflavones, Soy Essence containing additional isoflavones) were prepared to test the possibility that isoflavones might be sufficient for the effect observed on hair growth. Figure 18 shows the C57B1/6 mouse hair following three weeks of topical treatment, as described in example 4. Both untreated control mice and placebo treated mice have long and less "ordered" hair. Soymilk Essence 23 reduces hair growth and leads to a nicer appearance, as described earlier in this application. Soymilk Essence formulations containing 1, 5 and 10% of a 0.1% isoflavones containing extract result in a superior effect on hair growth. However, formulations containing isoflavones but no soymilk demonstrate milder, and not as superior effect as when combined with soymilk. This example demonstrates that soymilk formulations containing isoflavone could reduce hair growth. This example further demonstrates that soymilk formulations containing isoflavones reduce hair growth to a higher degree than formulations containing isoflavones alone. Example 12: Soy Essence formulations affect human hair growth The efficacy and irritancy potential of Soymilk Essence 23 and 3 0 compared to a placebo formulation were examined in a blinded placebo-controlled four-week test with twelve pre-menopausal female panelists ages 29 to 45 by evaluations by the study investigator, self- assessment by panelists and Hi-scope image analysis. Panelists signed an Informed Consent and were instructed about study procedures and expectations and were asked to shave that night. At the baseline visit the following day, two test lotions were distributed to each panelist (Day 1) , a placebo lotion and either soymilk Essence 23 or 30. The lotions were randomly assigned to either the right leg or left leg. The test lotions and placebo were used on the respective legs for the duration of the study with no other lotions used on the lower legs. Panelists were instructed to apply the test lotions twice daily, morning and evenings and were also instructed to try to refrain from shaving their lower legs until after each weekly evaluation. On evaluation days, the investigator visually inspected the panelists" legs for any clinical signs of irritation and compared legs for hair growth attenuation. Self-assessment questionnaires were completed by panelists at each evaluation time point (Weeks 1, 2, 3 and 4) . In addition, Hi-scope images (2.5 cm in diameter for each image, KH-2400R, Hirox) were obtained at each time point using a MX-MACROZ lens (Hirox). No panelists dropped from the study for any product-related reason. No signs of irritation were seen in any of the study panelists at any time point, nor was any irritation reported when self-assessed by panelists at any time point during the study. For the purpose of hair counts all hair, including "stubble", were counted in the given 2.5 cm field for each panelist at each time point. Results showed a decrease in lower leg hair counts by week 5 for Soymilk Essence 30 and by week 4 for Soymilk Essence 23. The placebo treated legs did not show a change in mean leg hair counts throughout the study although the standard deviations were large. The growth rate was calculated by dividing the length of time (in days) since the panelist last shaved, by the average length of leg hairs for that panelist, which was calculated from the hi- scope images using Image Pro Plus analysis for each panelist at each test site. The results are documented in Table 3, demonstrating that both Soymilk Essences 23 and 30 treatments resulted in reduced hair growth rate compared to placebo. Results from panelists" self-assessment questionnaires showed that panelists felt that the test lotions attenuated hair growth and softened the feel of leg hair, compared to the placebo lotion. Panelists felt that the hair felt less coarse and less stubbley. The majority of the panelists believed that the test lotions were attenuating leg hair growth or altering the texture of the hair so that it felt smoother and less coarse. Hi Scope analysis further demonstrated that the hair re-growth following treatment with Soymilk Essence 23 or 30 seemed to be growing in the same direction and was more uniform in shape, texture and appearance. In contrast, the hair that re-grew on the placebo- treated legs grew in different directions, differing in length, angle of growth and thickness. This Example clearly demonstrate the effect of soymilk formulations in delaying and reducing hair growth, and enabling the growth of softer, less coarse and more managed and directionally-organized hair. We Claim: 1. A composition for affecting changes in mammalian hair growth, hair pigmentation and hair shaft and follicle size, comprising topically applying to skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae. 2. The composition as claimed in claim 1, wherein the extract contains at least one serine protease inhibitory activity. 3. The composition as claimed in claim 2, wherein the at least one serine protease inhibitory active agent is present in an amount, based upon the total volume of the topically active composition, of from 0.0001% (w/v) to 20% (w/v). 4. The composition as claimed in claim 3, wherein the at least one protease inhibitory active agent is present in an amount, based upon the total volume of the topically active composition, of from 0.001% (w/v) to 5% (w/v). 5. The composition as claimed in claim 1, wherein the composition further comprises one or more isoflavones. 6. The composition as claimed in claim 1, wherein the composition further comprises one or more natural extracts containing one or more insoflavones. 7. The composition as claimed in claim 1, wherein the composition further comprises surfactants, moisturizers, humectants, foaming agents, cosmetic adjuvants, buffering agents, preservatives, anti- oxidants, conditioners, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, fragrances, colorants, or mixtures thereof. 8. The composition as claimed in claim 1, wherein said composition is in the form of liquid, cream, gel, paste, powder, essence, mousse, emulsion, film patch or spray. 9. The composition as claimed in claim 1, wherein said composition further comprises one or more products whose purpose is to either facilitate the removal of hair or actually remove hair or reduce hair visibility or improve hair management. 10. The composition as claimed in claim 1, wherein said composition further comprises one or more of the group consisting of: Depilatory cream, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair removal products, after-shave products deodorant, anti-perspirant, pre- or post- electrolysis products, pre- or post- laser hair removal products, pre- or post - light-induced hair removal products, pre- or post-light-induced hair removal products, mask, bath additives. 11. A composition as claimed in claim 1, wherein said compound is derived from legumes. 12. A composition as claimed in claim 11, wherein said compound is derived from soy, lima and/or black beans. 13. A composition as claimed in claim 12, wherein said compound is selected from the group consisting of soybean milk, limabean milk, blackbean milk, soybean extract, limabean extract, blackbean extract, soybean paste, limabean paste, blackbean paste, soybean powder, blackbean powder, limabean powder, soymilk powder, blackbean milk powder and limabean milk powder and mixtures thereof. 14. A composition as claimed in claim 13, wherein said compound is a fraction of soybean milk, soybean, extract, soybean paste, limabean milk, limabean extract, limabean paste, blackbean milk, blackbean extract, blackbean paste, soybean powder, blackbean powder, limabean powder, soymilk powder, blackbean milk powder and limabean milk powder and mixtures thereof. 15. A composition as claimed in claim 13, comprising bean milk in an amount of from 1 to 99% by weight. 16. A composition as claimed in claim 13, comprising soybean powder, soymilk powder or a mixture thereof in an amount of from 1 to 99% by weight. 17. A composition as claimed in claim 14, comprising soybean trypsin inhibitor, limabean trypsin inhibitor or blackbean trypsin inhibitor in an amount of from 0.0001 to 20% by weight. 18. A composition as claimed in claim 11, said composition further comprising one or more isoflavones. 19. A composition as claimed in claim 11, said composition further comprising one or more natural extracts containing one or more isoflavones. 20. A composition as claimed in claim 18, wherein said one or more isoflavones are present in said composition in amount of from 0.00001 to 0.1% by weight. 21. A composition as claimed in claim 19, wherein said one or more natural extract containing said one or more isoflavones are present in said composition in amount of from 0.00001 to 0.1% by weight. 22. A cosmetic composition as claimed in claim 1, said composition further comprising a cosmetically-acceptable vehicle. 23. A composition as claimed in claim 1, wherein said composition further comprises liposomes. 24. A composition as claimed in claim 23, wherein said composition comprises glycerol dilaurate, cholesterol, polyoxyethylene-10- stearyl ether and polyoxyethylene-9-lauryl ether. 25. A composition as claimed in claim 1, wherein said composition comprises from 1 to 99% bean milk, from 0.1 to 20% emulsifier and preservatives in an effective amount. 26. A composition as claimed in claim 1, wherein said composition comprises from 0.5 to 20% soybean powder or soymilk powder, from 0.1 to 20% emulsifier and preservatives in an effective amount. 27. A composition as claimed in claim 25, wherein said composition further comprises one or more isoflavones in an amount of from 0.00001 to 0.1%. 28. A composition as claimed in claim 25, wherein said composition further comprises one or more natural extracts comprising one or more isoflavons in an amount of from 0.0001 to 0.1%. 29. A composition as claimed in claim 1, wherein said composition further comprises one or more isoflavones in an amount of from 0.0001 to 0.1%. 30. A composition as claimed in claim 26, wherein said composition further comprises one or more natural extracts comprising one or more isoflavones in an amount of from 0.0005 to 0.05%. A composition for affecting changes in mammalian hair growth, hair pigmentation and hair shaft and follicle size, comprising topically applying to skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.

Full Text

REDUCING HAIR GROWTH, HAIR FOLLICLE AND HAIR SHAFT SIZE
AND HAIR PIGMENTATION
Miri Seiberg, Stanley Shapiro, Jue-Chen Liu, Jonathan
Miller
Field of the Invention
This invention is related to methods and
compositions effective for reducing hair growth. More
specifically, the present invention is directed to
methods for changing the rate of hair growth, reducing
the size of the hair follicle and the hair shaft, and
reducing hair shaft pigmentation, by topical application
of either botanical extracts containing serine protease
inhibitory activity and in particular soybean extracts
such as soymilk, or mixtures and formulations of the
above, combined with other active ingredients such as
isoflavones.
Background of the Invention
One main function of mammalian hair is to provide
environmental protection. However, that function has
largely been lost in humans, in whom hair is kept or
removed essentially for social and cosmetic purposes.
Many procedures are used to remove unwanted hair
including shaving, electrolysis, plucking, laser and
light therapies and injection of therapeutic
antiandrogens. These conventional methods are not
without their shortcomings. Shaving, for instance, may
result in nicks and cuts in the skin"s surface, may
leave a perception of an increase in the rate of hair
regrowth, and may also leave undesirable stubble. While
electrolysis may keep an area free of unwanted hair for
a prolonged period of time, the process is often
expensive and painful and may further result in
scarring. Not only may plucking cause pain and
discomfort, but it often result in a poor removal of
short hair. Several unwanted side effects, such as
effects on muscularity, often accompany the use of
antiandrogens. For these reasons, better methods for
reducing hair growth are needed.
Pseudofolliculitis barbae is an inflammatory hair
disorder, most commonly found on the beard area.
Inflammatory follicular papules result when hair tips
penetrate into the skin rather than passing through the
follicular orifice. This process is extremely common in
black men because their hairs are frequently curly,
exiting the skin at an acute angle. Close shaves,
particularly with a razor blade, predispose them to
pseudofolliculitis barbae. The most effective treatment
available is to allow the hairs to grow well beyond the
skin surface. Such a treatment is often not desired.
Hirsutism is a relatively frequent condition
affecting about 4% of women. Facial hirsutism often
interferes with personal and work activities, and
temporary hair removal is a major component in the
management of hirsute patients. Shaving is the most
frequently used temporary method for facial hair, as
plucking, waxing and depilatories are more difficult to
tolerate and care must be taken to avoid folliculitis,
pigmentation, and scarring. Cosmetic cover-ups are
usually used to hide cuts and stubble and electrolysis
and thermolysis may be used for permanent hair removal
when affordable.
An alternative or complementary desired approach to
hair removal, would be a method to reduce hair growth,
reduce hair follicle and hair shaft size and reduce hair
shaft pigmentation. Such an approach could reduce the
visibility of existing hair, making it softer and
lighter. When combined with other methods of hair
removal such a method could enhance and prolong the
removal effect, and reduce the need and frequency of
hair removal. Long term use of such an approach could
lead to attenuated, soft, pigmentation-reduced hair
growth, that is less visible and does not require the
use of other removal methods.
Reduced hair growth is desired in the axilla area
(fossa axillaris), where deodorants and anti-perspirants
are used to control odor trapped within the axillary
hairs. It would be desired to have products for under-
arm use, which combine deodorant or anti-perspirant
activities with reduced hair growth activity.
African type hair is unique in its morphology -- a
kinky hair shaft with variations in diameter. This
complex shaft structure creates the need for specialized
grooming products and procedures to ensure that the
African type hair maintains cosmetic desired properties.
It is desired to have products that reduce this
complexity and make the African type hair more
manageable, improving its appearance.
It would be desirable to provide a method for
chemically or naturally affecting hair growth, hair
follicle and hair shaft size and hair shaft
pigmentation, which does not cause unwanted side effects
to the user.
Summary of the Invention
In accordance with the present invention, we
have found compositions and methods for affecting
changes in mammalian hair growth, hair follicle and hair
shaft size and hair pigmentation by topically applying
to the skin of a mammal an effective amount of a
topically active composition comprising protease
inhibitors, botanical extracts, and in particular legume
extracts including, but not limited to, soymilk, for a
period of time sufficient to affect hair growth, hair
follicle and hair shaft size and hair shaft
pigmentation. Such topically active compositions may be
further combined with other active ingredients
including, but not limited to, synthetic or naturally-
occurring isoflavones, to enhance the desired effects on
hair growth and pigmentation.
The compositions and methods of this invention
provide a unique, convenient means for delaying hair
growth, reducing hair follicle and hair shaft size and
hair shaft pigmentation, by using serine protease
inhibitors, botanical extracts of the legume family, and
in particular, but not limited to, soymilk, containing
serine protease inhibitory activity, and their
combinations with isoflavones.
Brief Description of the Drawings
The file of this patent contains at least one
drawing executed in color. Copies of this patent with
color drawing (s) will be provided by the Patent and
Trademark Office upon request and payment of the
necessary fee.
The invention will be more fully understood and
further advantages will become apparent when reference
is made to the following detailed description of the
invention and the accompanying drawings in which:
Figure 1: A photograph of control and soymilk treated
C57B1/6 mouse hair (high magnification).
Figure 2: Histological sections of control and soymilk-
treated C57B1/6 mouse hair follicles at day four of the
hair cycle.
Figure 3: Histological sections of control and soymilk-
treated C57B1/6 mouse hair follicles at day seven of the
hair cycle, high and low magnifications.
Figure 4: Histological sections of control and soymilk-
treated C57B1/6 mouse hair follicles at day 18 of the
hair cycle.
Figure 5: Histological sections of control and soymilk-
treated C57B1/6 mouse hair follicles at day 21 of the
hair cycle.
Figure 6: Histological sections of control, soymilk, and
soymilk-derived proteins-treated C3H mouse hair
follicles (High magnification) at day seven of the hair
cycle.
Figure 7: Histological sections of control, soymilk, and
soymilk-derived proteins-treated C3H mouse hair
follicles (lower magnifications) at day seven of the
hair cycle.
Figure 8: Histological sections of control and soymilk-
treated C3H mouse hair follicles at day 21 of the hair
cycle.
Figure 9: A photograph of control and soymilk-derived
proteins treated C3H mouse hair (high magnification).
Figure 10: Histological sections of control and soymilk-
derived proteins-treated C57B1/6 mouse hair follicles
(High magnification) at day eight of the hair cycle.
Figure 11: A graph demonstrating the trypsin inhibitory
activity of soymilk.
Figure 12: Western blot of C57B1/6 mouse skins
throughout the hair cycle, demonstrating reduced
tyrosinase and TRP-1 protein levels following soymilk
treatment.
Figure 13: Photographs of untreated and soymilk treated
sides of human face, treated with soymilk daily for four
weeks.
Figure 14: Quantitative analysis of hair follicle
dimensions with and without soymilk treatment.
Figure 15: Photographs of human leg hair following five
weeks of soymilk treatment on one leg.
Figure 16: Photographs of control, soymilk, and
isoflavone-enriched soymilk treated C57B1/6 mouse hair
(high magnification).
Figure 17: Histological sections of control, soymilk,
and isoflavone-enriched soymilk treated C57B1/6 mouse
skins at day 15 of the hair cycle, documenting the
thickness and color of the hair shafts.
Figure 18: Photograph of C57B1/6 mouse hair after three
weeks of treatment with various soymilk and isoflavones
formulations.
Detailed Description of Preferred Embodiments
As used herein, "mammal" shall mean any member "of
the higher vertebrate animals comprising the class
Mammalia," as defined in Webster"s Medical Desk
Dictionary 407 (1986) , and includes but is not limited
to humans. As used herein "(%, w/v)" shall mean grams
of a given component per 100 ml of the total
composition.
Topically active agents suitable for use in the
composition of the present invention include protease
inhibitors and natural plant extracts having protease
inhibitory activity and mixtures thereof. Preferred
protease inhibitors are serine protease inhibitors, and
in particular Soybean Trypsin Inhibitor ("STI") and the
soybean-derived Bowman Birk Inhibitor ("BBI). Preferred
botanical extracts are of the legume family and in
particular bean extracts, such as soymilk. Preferably,
the protease inhibitors are present in an amount, based
upon the total volume of the composition of the present
invention, of from about 0.0001% (w/v) to about 20%
(w/v), and more preferably from about 0.001% (w/v) to
about 5% (w/v). Preferably, botanical aqueous extracts
such as soymilk are present in an amount of 10-99%
(v/v), and more preferably from 50-99% (v/v).
We have unexpectedly found that when topically
active agents such as described above, and in particular
soymilk or soymilk containing formulations, are enriched
with isoflavones, and in particular soybean-derived
isoflavones, the inhibitory effect on hair growth, hair
dimensions and hair pigmentation is enhanced.
Preferably, the isoflavones are present in the botanical
aqueous extracts such as soymilk in an amount of
0.000005-15% (v/v), and more preferably from 0.00001-10%
(v/v) .
If the delivery parameters of the topically active
pharmaceutical or cosmetic agent so require, the
topically active composition of the present invention
may be further comprised of a pharmaceutically or
cosmetically acceptable vehicle capable of functioning
as a delivery system to enable the penetration of the
topically active agent into the hair follicle and the
skin.
The pharmaceutical or cosmetic composition may be
optionally combined with other ingredients such as
moisturizers, cosmetic adjuvants, anti-oxidants,
depigmenting agents, anti-aging agents, hair removal
agents, hair styling agents, sunscreens surfactants,
foaming agents, conditioners, humectants, fragrances,
colorants, viscosifiers, buffering agents,
preservatives, and the like and mixtures thereof. These
will be combined in an amount which will not affect the
serine protease inhibitory activity, in order to produce
cosmetic or pharmaceutical products such as, non-
exclusively, essences, creams, lotions, pastes, gels,
powders, patches or injectables and the like for the
reduction of hair growth, hair size and hair
pigmentation.
The compositions of this invention may be applied
prior to, concurrently with or after other active
ingredients or compositions to enhance their effect.
For example, the compositions of this invention may be
applied in conjunction with one or more products whose
purpose is to facilitate the removal of hair to to
actually remove hair, reduce hair visibility, improve
hair style or improve hair management. The compositions
of this invention may be applied topically prior to,
during or following hair removal. They may be applied
topically concurrently with one or more of the following
group: depilatory agents, shampoo, hair conditioner,
styling gel, hair care products, waxing products,
shaving products, hair-removal products, after-shave
products, deodorant, anti-perspirant, electrolysis,
laser hair removal, light-induced hair removal, mask or
bath additives.
The compositions of this invention may be applied
daily for at least four to eight weeks, by which an
effect upon the appearance of hair should be observed.
Application may be continued as long as desired to
maintain the condition of the hair. Daily application
to the face may mitigate the condition of
pseudofolliculitis barbae and/or hirsutism; application
to the axillary area may reduce hair growth under the
arms and application to the scalp and hair may assist in
managing and styling African-type hair.
The topically active pharmaceutical or cosmetic
composition should be applied in an amount effective to
effect changes in mammalian hair growth, hair follicle
and hair shaft size and hair shaft pigmentation. As
used herein "amount effective" shall mean an amount
sufficient to cover the region of skin surface where a
delay in hair growth and hair pigmentation and reduced
hair size are desired. Preferably, the composition is
applied to the skin surface such that, based upon a
square cm of skin surface, from about 2 µl /cm2 to about
500 µl /cm2 of topically active agent is present when a
delay in hair growth, hair size and hair pigmentation is
desired.
We have unexpectedly found that when topically
active agents, such as soymilk, or isoflavone-enriched
soymilk are topically applied to an animal"s skin, a
significant delay in hair growth, hair follicle and hair
shaft size and hair shaft pigmentation was achieved. We
further believe that since the hair growth cycle for
humans is often slower than that for mice, it is further
likely that the hair growth delay in humans would be
considerably longer than in mice.
The invention illustratively disclosed herein
suitably might be practiced in the absence of any
component, ingredient, or step which is not specifically
disclosed herein. Several examples are set forth below
to further illustrate the nature of the invention and the
manner of carrying it out. However, the invention should
not be considered as being limited to the details
thereof.
Examples
EXAMPLE 1; Depilation of Test Subjects in the Mouse
System
C57BI/6 or C3H mice (male and female) were obtained
from Charles River (Kingston, NY) , at 8 -10 weeks of age
and were in the resting (telogen) phase of their
respective hair cycle. Hair growth was induced by wax
depilation (plucking) of each respective animal"s back
fur according to the procedure set forth in Stenn, et
al., "Glucocorticoid Effect on Hair Growth Initiation: A
Reconsideration," 6 Skin Pharmacol. , 125 -134 (1993).
In C57B1/6 and C3H mice, 8-10 weeks old, the growth
phase (anagen) starts synchronously in all hair
follicles at the time of depilation. As illustrated in
Table 1, the following observations were noticed at the
induction site:
As shown in Table 1, the hair growth was visible several
days after depilation as the pink skin of the animal
began to darken. This is likely due to hair
pigmentation in the shaft since the C57BI/6 and C3H mice
contained melanocytes only in the hair follicles and not
in the dorsal epidermis. Similar hair growth pattern
was documented in our international application No.
PCT/US 97/11033, when chemical depilation using
commercially available products was performed.
Since the murine hair cycle varies not only between
strains, but also amongst individual animals, the status
of the hair cycle was analyzed in each animal on study.
A 2 cm by 1 cm skin sample was isolated from each mouse
with scissors, fixed with a 10% buffered formalin
solution having a pH of about 6.9 - 7.1 at 25 °C
(Stephens Scientific), and then formed into a paraffin
block according to well-known procedures. The block was
then microtomed, and sections were stained with H&E or
Fontana-Mason stain. Sections were examined
histologically in order to verify the phase of the hair
cycle, the size of the hair follicle and hair shaft and
the level of hair pigmentation, using procedures well
known in the art. Hair length was assessed visually,
and by using a low magnification (x8) dissecting
microscope.
This Example, as well as the one described in our
international application No. PCT/US 97/11033, shows
that the hair growth cycle for C57BI/6 and C3H mice
averaged about 25 days and reports similar timing of
hair follicle and shaft development regardless of the
method used for depilation.
EXAMPLE 2; Preparation of soymilk and sovmilk
formulations
One way to make soymilk is to soak the soybeans in
deionized or purified water for several hours, and grind
them after they were fully hydrated, with the addition
of small quantities of water. (The grinding process
allows the soybean milk to be extracted). After
collection, the soybean milk may be filtered to remove
any residual parts of the bean husk. The soymilk used
in the formulations described below can be fresh soymilk
as described above, or may be made from soybean powder
and water. The soybean powder is milled from soybeans
and may also be lyophilized, spray dried, or freeze-
dried and the resulting soymilk may or may not be
filtered. Such prepared soymilk may have from about 1 to
about 90% by weight dry soybean powder. Another example
is the use of soymilk powder, made from lyophilized,
spray dried or freeze-dried soymilk, with the addition
of water and finished with or without filtration or
homogenization. Other methods of soybean extraction
could also be used to create the active ingredients in
the formulations described below. For example, the
active ingredients could be extracted from ground
soybeans using ethanol/water mixtures, followed by the
removal of the ethanol from the extract, in such ways
that the serine protease inhibitory activity of the
soybean will be retained, and preferably that the
protein STI will remain intact.
The soy products useful in this invention may be
produced from all soybean species, regardless of their
geographic origin, sun exposure, harvest time and the
like. However, specific strains, geographic origins or
growth conditions might be preferred. For example, but
not limiting to, soybean strains particularly rich in its
Soybean Trypsin Inhibitor (STI) content or in isoflavone
content, or growth conditions that result in STI or
isoflavone enrichment in the bean, might be preferred.
It should be noted that the soy products useful in the
compositions of this invention have a distinctive odor,
which may be tolerable in some cultures, but is undesired
in others. If necessary, the odor of the compositions of
this invention may be reduced by using soybean products
derived from specific strains of soybeans known to
produce reduced-odor, including, but not limited to,
lipoxygenase-2-deficient beans and those having modified
sugar profile, and the like. A process to reduce oxygen
levels in the formulation may also reduce the odor.
Various masking agents or fragrances may also be used to
mask the odor.
The compositions of this invention may further comprise
surfactants, moisturizers, humectants, conditioners,
fragrances, colorants, preservatives, anti-oxidants,
depigmenting agents, hair removal agents, anti-aging
agents, sunscreens, foaming agents, cosmetic adjuvants,
buffering agents or mixtures thereof.
The compositions of this invention may be left on the skin
for a period sufficient to effect changes. For example,
the compositions of this invention may be applied to the
skin daily treatment for at least about four weeks, more
preferably, the composition should applied daily for at
least eight weeks.
Another method according to this invention is a method to
reduce or prevent pseudofolliculitis barbae. Daily
application of the compositions of this i nvention may
reduce or prevent this condition. The compositions of this
invention may also be applied daily to the axilliary area
to reduce hair growth. Furthermore, the compositions of
this invention may be applied daily to the scalp to style
and improve management of African type hair.
As shown in our co-pending U.S. Patent Application
(Attorney Docket No. JBP 430), numerous soymilk-based
formulations could be used to reduce pigmentation. All
these formulations could also be used to reduce hair
growth. Some particularly preferred examples of soymilk
formulations and soymilk formulations containing
isoflavones are shown in table 2 below. An example for
an isoflavones preparation that could be used in this
invention is Flavosterone SE from Ichimaru, Japan, which
contains about 0.1% pure isoflavones. In all these
formulations, soymilk could be replaced with the
appropriate quantities of soybean powder or soymilk
powder and water.
EXAMPLE 3: Preparation of Topically Active Compositions
containing soybean derived protease inhibitors
Soybean trypsin inhibitor (STI) and Bowman-Birk
inhibitor (BBI), from Sigma-Aldrich Corporation were
mixed into a 0.1M phosphate buffered saline (PBS, Gibco-
BRL, Gaithersburg, MA), pH 7.4, in concentrations of 1%
to 0.001% (w/v) . Four volumes of the resulting
solutions were then mixed with 1 volume of (100 mg/ml)
liposomes vehicle, which was prepared by the methods
described in Niemiec et. al, in order to yield the
topically active composition. Non-ionic liposomes
preparations, such as those disclosed in Niemiec et al.,
"Influence of Nonionic Liposomal Composition On Topical
Delivery of Peptide Drugs Into Pilosebaceous Units: An
In Vivo Study Using the Hamster Ear Model," 12 Pharm.
Res. 1184-88 (1995) ("Niemiec"), which is incorporated
by reference herein in its entirety, are well known in
the art, and are described our U.S. Patent Application
(Attorney Docket No. JBP 430) . GDL liposomes were
prepared as set forth in Niemiec, et al., above, with
the exception of the following changes: the non-ionic
liposomal formulation contained glycerol dilaurate
(Emulsynt GDL, ISP Van Dyk)/cholesterol
(Croda)/polyoxyethylene-10-stearyl ether (Brij76,
ICI)/polyoxyethylene-9-lauryl ether, as at ratio of
37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M,
pH 7.4 (Gibco-BRL of Gaithersburg, MD) were used as the
aqueous phase in the preparation of the liposomes.
EXAMPLE 4; Soymilk Delays Hair Growth and reduce hair
follicle and hair shaft size and Hair shaft Pigmentation
C57B1/6 mice were induced for a new hair cycle as
described in Example 1, and treated daily with soymilk.
Animals were observed daily for their hair growth
pattern, and skin biopsies were taken at important time
points of the hair cycle. As a result of soymilk
treatment the hair growth of the treated mice was
delayed, and their hairs were visibly thinner, and
smoother to touch. Treated mice did not show skin
darkness at days 7-8 of the hair cycle, as expected, and
hair shafts were not visible at days 11-12 as in the
control animals. In average, the hair cycle of the
soymilk treated mice was delayed by 3-6 days. Figure 1
is a picture of the mice fur, showing the difference in
hair appearance, color, size and thickness following
soymilk treatment.
Histological examination of the biopsied skin
samples confirmed these observations. As shown in
Figure 2 by Fontana-Mason (F&M) staining, at day four of
the hair cycle the untreated hair follicle is fully
developed, as expected, containing all the cellular
layers and pigment deposition. In contrast, the soymilk
treated sample, (shown at same magnification), shows a
smaller and not as fully developed hair follicle, with
no pigment deposition.
Figure 3 shows two sets of histological sections
stained with F&M, of lower and higher magnification.
These sections are from day seven of the hair cycle.
The upper panel shows that soymilk treated skin has
smaller, shorter, and less pigmented hair follicles than
the untreated control. The lower panel shows a higher
magnification of the follicles, further demonstrating
the difference in hair follicle and hair shaft size and
pigmentation following soymilk treatment.
Figure 4 shows low magnification of F&M stained
skin sections at day 18 of the hair cycle. At this
magnification it is obvious that soymilk treatment
results in reduced hair follicle size, which leads to
reduced hair shaft length and thickness, and reduced
total pigment deposition within the treated follicles.
Figure 5 shows skin sections at day 21 of the hair
cycle, with two magnifications. The upper panel
demonstrates that the control animals were in the
catagen stage, when hair follicles are regressing.
Soymilk treated follicles, on the other hand, had
already completed the catagen stage, as they are shown
in telogen, the resting stage. This indicates that not
only the hair cycle was delayed following soymilk
treatment, it was also prematurely terminated. The
lower panel demonstrates the catagen control follicle
and the shorter, telogen (resting) soymilk-treated
follicle using higher magnification.
EXAMPLE 5; The effects of soymilk on hair growth, size
and pigmentation are reproducible in C3H mice
In order to verify that the effect of soymilk on
hair growth is not specific to C57B1/6 mice, we repeated
the experiment described in Example 4 using the brown
haired (Agouti) C3H mice. The results of these
experiments were similar both visually and
histologically. Soymilk delayed hair growth and reduced
hair follicle and hair shaft size and pigment deposition
in the C3H mice.
Histological analysis confirmed these visual
observations. As shown in the upper panel of Figure 6,
using F&M staining, at day seven of the hair cycle
soymilk treated follicles are smaller and accumulate
less pigment than untreated controls. The upper panel
of Figure 7 (F&M staining) shows a lower magnification
of the same skin sections, demonstrating the thinner and
less pigmented follicles following soymilk treatment.
Figure 8 shows F&M stained skin sections at day 21
of the hair cycle. As shown for the C57B1/6 mice,
following soymilk treatment the hair cycle terminates
prematurely. Soymilk treated follicles are in the
resting state, while untreated control follicles are
still in catagen.
EXAMPLE 6; The effects of soymilk and soybean derived
serine protease inhibitors on hair growth, size and
pigmentation
In search for a mechanism to explain the effect of
soymilk on hair growth, we tested the effect of the
soymilk-derived serine protease inhibitors, STI and BBI.
We had shown earlier that these proteins induce
depigmentation in skin, by affecting the PAR-2 pathway
(U.S. Patent Application, Attorney Docket No. JBP 430) .
The experiments described in Example 4 were
repeated using STI, BBI, and soymilk. STI and BBI were
used in a PBS-liposome vehicle as described in Example
3. Visual observations throughout the hair cycle
confirmed that both STI and BBI could delay hair growth
and reduce hair follicle and hair shaft size, similar to
soymilk (see hair pictures in Figure 9) . Using high
concentrations of STI or BBI, the effect on hair growth
and pigmentation was substantial.
Histological analysis confirmed these finding. As
shown in Fig. 6, at day seven of the hair cycle 1% of
STI and 1% of BBI reduce hair follicle and hair shaft
size and hair shaft pigmentation in C3H mice. Figure 7
shows lower magnification sections of the same day into
the hair cycle, demonstrating smaller hair follicles and
hair shafts and reduced pigmentation, relative to
untreated control, with soymilk, STI or BBI treatment.
Figure 10 shows that STI and BBI have the same effect in
C57B1/6 mice too, demonstrating smaller and less
pigmented follicles. Taken together, this example shows
that STI and BBI are soybean-derived serine protease
inhibitors, found in soymilk, that could delay hair
growth, reduce hair follicle and hair shaft size and
reduce hair pigmentation. STI and BBI could represent a
part of the soymilk ingredients that affects hair
growth.
In order to support the hypothesis that STI and BBI
in soymilk are involved in the hair growth effects
described above, we tested soymilk for its serine
protease inhibitory activity. An enzymatic assay was
performed using "Enzchek", a protease digestion
fluorescent test system made by Molecular Probes of
Eugene, OR. Using 100 units of trypsin (from Sigma
chemicals, St. Louis MO) the test system produced
fluorescence reading of about 1100 units. This reaction
was inhibited with increasing concentrations of STI, as
expected from a known trypsin inhibitor. Serial
dilutions of soymilk were tested in this assay, and
found to inhibit trypsin activity. As shown in Figure
11, soymilk exerts trypsin inhibitory activity similar
to about 0.2% of pure STI. This suggests that soymilk
could exert its hair growth effect, at least in part, by
STI and BBI.
EXAMPLE 7:___Soymilk Induces Chancres in Tyrosinase and
TRP-1 protein expression
The histological analyses of soymilk treated skin
samples described in the examples above show dramatic
reduction in pigment deposition within the hair
follicle. To further understand the mechanism of
soymilk-induced depigmentation, we studied tyrosinase,
the key enzyme in melanogenesis and Tyrosinase-Related
Protein-1 (TRP-1), the enzyme that stabilizes
tyrosinase. C57B1/6 and C3H mice were treated as
described above, and samples were collected throughout
the study for protein analysis. Protein extraction and
Western blot analysis were performed using standard
procedures, such as the one described in Current
Protocols in Cell Biology, Edited by Juan S. Bonifacino
et al. Chapter 6: Electrophoresis and Immunoblotting.
Copyright 1999 by John Wiley & Sons, Inc., which is
incorporated herein by reference in its entirety. An
example of one such study is shown in Figure 12.
Equal amounts of skin-extracted proteins were probed
with the anti-tyrosinase antibody "anti PEP1", and with
the anti-TRP-1 antibody "anti PEP7" which are described
in Jimenez, M., Kameyama, K., Maloy, WL, Tomita Y., and
Hearing, V. Mammalian tyrosinase: biosynthesis,
processing and modulation by melanocyte stimulating
hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34,
and Jimenez, M., K., Maloy, WL, and Hearing, V.
Specific identification of an authentic tyrosinase
clone. J. Biol. Chem. (1989) 264:3397-3403, which are
incorporated herein by reference in their entirety.
As shown in Figure 12, The expression of Tyrosinase
and TRP-1 proteins is dramatically affected by soymilk
treatment. Tyrosinase and TRP-1 levels are reduced, and
the duration of the expression is shortened. These two
factors affect overall hair pigmentation, which is
reduced due to the reduced level and shorter duration of
melanogenesis.
EXAMPLE 8; Soymilk reduces human facial hair lenath and
thickness
An individual male with dark facial hair who shaves
daily was treating the right side of his face with
soymilk, immediately after shaving, for five weeks. By
the third week, and more noticeably by the forth week,
the hair of the treated side was visually lighter and
felt smoother to touch. Digital pictures at different
magnifications were taken throughout the treatment
period, using Hi-Scope. These pictures clearly
demonstrate the reduced size and thickness of the hair
shafts at the treated side. An example of such pictures
is shown in Figure 13, demonstrating the difference in
hair shaft thickness and density at four weeks of
treatment. Since both sides of the face were shaved at
the same time, and pictures of both sides were taken at
the same time, the difference in length of the facial
hair indicates slower growth rate at the treated area.
Figure 14 shows a computerized image analysis of
the facial hair length, thickness and total area,
following four weeks of soymilk treatment. All images
were analyzed with Image Pro Plus 3.0 software (Media
Cybernetics, Silver Spring, MD) . Data are presented as
average of 180 hair shafts of each side of the face,
with standard deviation (SigmaPlot® 5.0, SPSS Science,
Chicago, IL) . Statistical analysis was performed using
SigmaStat® 2.0 (SPSS Science) software, demonstrating a
statistical significant difference in all measured
parameters, following soymilk treatment.
EXAMPLE 9; Soymilk reduces human legs hair length and
thickness
Hair was wax-depilated of two symmetrical areas of
the medial part of the legs, below the knee, in one
individual. One leg was treated daily, for four weeks,
with soymilk. Visual observations indicate slower hair
growth on the treated site. Hair shafts were reduced in
number and were shorter and thinner than those of the
untreated site, as shown in Figure 15. These
observations further confirm the effect of soymilk on
hair growth. Examples 8 and 9 together confirm that the
effect of soymilk on human hair growth is not related to
the method of hair removal or to the body part being
treated.
EXAMPLE 10:______Soymilk formulations enriched with
isoflavones are preferred to soymilk formulations in
reducing hair growth and pigmentation.
The experiments described in Example 4 were
repeated, using two formulations described in Table 2
above, Soymilk Essence 23 which is a soymilk-based
formulation, and soymilk Essence 30 which is identical
to Soymilk Essence 23 except the addition of 5% of a
0.1% isoflavones extract. As shown in Figure 16, mice
treated with Soymilk essence 23 show reduced hair growth
and nicer hair appearance. This effect was more
pronounced with the use of soymilk Essence 30,
demonstrating that isoflavone-enriched soymilk
formulations are superior to soymilk formulations in
reducing hair growth. Figure 17 shows histological skin
sections of the treated mice, at day 15 of the
treatment. The hair shafts documented in these sections
clearly demonstrate the reduction in hair shaft
dimensions, the reduced level of pigmentation within the
hair shaft, and the increased smoothness of the hair
shaft following the Soymilk Essence treatments.
EXAMPLE 11;______Soymilk formulations enriched with
isoflavonea are preferred to isoflavone formulations
which are effective in reducing hair growth and
pigmentation.
The experiments described in Example 4 were
repeated, using formulations described in Table 2 above,
of soymilk essence with or without increasing
concentrations of isoflavones. These Soy Essence
formulations were compare to similar formulations, where
the soymilk component only was replaced with water.
These three sets of formulations (Soy Essence,
isoflavones, Soy Essence containing additional
isoflavones) were prepared to test the possibility that
isoflavones might be sufficient for the effect observed
on hair growth. Figure 18 shows the C57B1/6 mouse hair
following three weeks of topical treatment, as described
in example 4. Both untreated control mice and placebo
treated mice have long and less "ordered" hair. Soymilk
Essence 23 reduces hair growth and leads to a nicer
appearance, as described earlier in this application.
Soymilk Essence formulations containing 1, 5 and 10% of
a 0.1% isoflavones containing extract result in a
superior effect on hair growth. However, formulations
containing isoflavones but no soymilk demonstrate
milder, and not as superior effect as when combined with
soymilk. This example demonstrates that soymilk
formulations containing isoflavone could reduce hair
growth. This example further demonstrates that soymilk
formulations containing isoflavones reduce hair growth
to a higher degree than formulations containing
isoflavones alone.
Example 12: Soy Essence formulations affect human hair
growth
The efficacy and irritancy potential of Soymilk
Essence 23 and 3 0 compared to a placebo formulation were
examined in a blinded placebo-controlled four-week test
with twelve pre-menopausal female panelists ages 29 to
45 by evaluations by the study investigator, self-
assessment by panelists and Hi-scope image analysis.
Panelists signed an Informed Consent and were instructed
about study procedures and expectations and were asked
to shave that night. At the baseline visit the
following day, two test lotions were distributed to each
panelist (Day 1) , a placebo lotion and either soymilk
Essence 23 or 30. The lotions were randomly assigned to
either the right leg or left leg. The test lotions and
placebo were used on the respective legs for the
duration of the study with no other lotions used on the
lower legs. Panelists were instructed to apply the test
lotions twice daily, morning and evenings and were also
instructed to try to refrain from shaving their lower
legs until after each weekly evaluation. On evaluation
days, the investigator visually inspected the panelists"
legs for any clinical signs of irritation and compared
legs for hair growth attenuation. Self-assessment
questionnaires were completed by panelists at each
evaluation time point (Weeks 1, 2, 3 and 4) . In
addition, Hi-scope images (2.5 cm in diameter for each
image, KH-2400R, Hirox) were obtained at each time point
using a MX-MACROZ lens (Hirox).
No panelists dropped from the study for any
product-related reason. No signs of irritation were
seen in any of the study panelists at any time point,
nor was any irritation reported when self-assessed by
panelists at any time point during the study.
For the purpose of hair counts all hair, including
"stubble", were counted in the given 2.5 cm field for
each panelist at each time point. Results showed a
decrease in lower leg hair counts by week 5 for Soymilk
Essence 30 and by week 4 for Soymilk Essence 23. The
placebo treated legs did not show a change in mean leg
hair counts throughout the study although the standard
deviations were large. The growth rate was calculated
by dividing the length of time (in days) since the
panelist last shaved, by the average length of leg hairs
for that panelist, which was calculated from the hi-
scope images using Image Pro Plus analysis for each
panelist at each test site. The results are documented
in Table 3, demonstrating that both Soymilk Essences 23
and 30 treatments resulted in reduced hair growth rate
compared to placebo.
Results from panelists" self-assessment questionnaires
showed that panelists felt that the test lotions attenuated
hair growth and softened the feel of leg hair, compared to
the placebo lotion. Panelists felt that the hair felt less
coarse and less stubbley. The majority of the panelists
believed that the test lotions were attenuating leg hair
growth or altering the texture of the hair so that it felt
smoother and less coarse. Hi Scope analysis further
demonstrated that the hair re-growth following treatment with
Soymilk Essence 23 or 30 seemed to be growing in the same
direction and was more uniform in shape, texture and
appearance. In contrast, the hair that re-grew on the
placebo- treated legs grew in different directions, differing
in length, angle of growth and thickness.
This Example clearly demonstrate the effect of soymilk
formulations in delaying and reducing hair growth, and
enabling the growth of softer, less coarse and more managed
and directionally-organized hair.
We Claim:
1. A composition for affecting changes in mammalian hair growth,
hair pigmentation and hair shaft and follicle size, comprising
topically applying to skin of a mammal an effective amount of a
topically active composition comprising one or more compounds
derived from one or more of the botanical families leguminosae,
solanaceae, gramineae and cucurbitaceae.
2. The composition as claimed in claim 1, wherein the extract
contains at least one serine protease inhibitory activity.
3. The composition as claimed in claim 2, wherein the at least one
serine protease inhibitory active agent is present in an amount,
based upon the total volume of the topically active composition, of
from 0.0001% (w/v) to 20% (w/v).
4. The composition as claimed in claim 3, wherein the at least one
protease inhibitory active agent is present in an amount, based
upon the total volume of the topically active composition, of from
0.001% (w/v) to 5% (w/v).
5. The composition as claimed in claim 1, wherein the composition
further comprises one or more isoflavones.
6. The composition as claimed in claim 1, wherein the composition
further comprises one or more natural extracts containing one or
more insoflavones.
7. The composition as claimed in claim 1, wherein the composition
further comprises surfactants, moisturizers, humectants, foaming
agents, cosmetic adjuvants, buffering agents, preservatives, anti-
oxidants, conditioners, depigmenting agents, hair removal agents,
anti-aging agents, sunscreens, fragrances, colorants, or mixtures
thereof.
8. The composition as claimed in claim 1, wherein said composition
is in the form of liquid, cream, gel, paste, powder, essence,
mousse, emulsion, film patch or spray.
9. The composition as claimed in claim 1, wherein said composition
further comprises one or more products whose purpose is to either
facilitate the removal of hair or actually remove hair or reduce hair
visibility or improve hair management.
10. The composition as claimed in claim 1, wherein said composition
further comprises one or more of the group consisting of:
Depilatory cream, shampoo, hair conditioner, styling gel, hair care
products, waxing products, shaving products, hair removal
products, after-shave products deodorant, anti-perspirant, pre- or
post- electrolysis products, pre- or post- laser hair removal
products, pre- or post - light-induced hair removal products, pre-
or post-light-induced hair removal products, mask, bath additives.
11. A composition as claimed in claim 1, wherein said compound is
derived from legumes.
12. A composition as claimed in claim 11, wherein said compound is
derived from soy, lima and/or black beans.
13. A composition as claimed in claim 12, wherein said compound is
selected from the group consisting of soybean milk, limabean milk,
blackbean milk, soybean extract, limabean extract, blackbean
extract, soybean paste, limabean paste, blackbean paste, soybean
powder, blackbean powder, limabean powder, soymilk powder,
blackbean milk powder and limabean milk powder and mixtures
thereof.
14. A composition as claimed in claim 13, wherein said compound is a
fraction of soybean milk, soybean, extract, soybean paste,
limabean milk, limabean extract, limabean paste, blackbean milk,
blackbean extract, blackbean paste, soybean powder, blackbean
powder, limabean powder, soymilk powder, blackbean milk
powder and limabean milk powder and mixtures thereof.
15. A composition as claimed in claim 13, comprising bean milk in an
amount of from 1 to 99% by weight.
16. A composition as claimed in claim 13, comprising soybean
powder, soymilk powder or a mixture thereof in an amount of from
1 to 99% by weight.
17. A composition as claimed in claim 14, comprising soybean trypsin
inhibitor, limabean trypsin inhibitor or blackbean trypsin inhibitor
in an amount of from 0.0001 to 20% by weight.
18. A composition as claimed in claim 11, said composition further
comprising one or more isoflavones.
19. A composition as claimed in claim 11, said composition further
comprising one or more natural extracts containing one or more
isoflavones.
20. A composition as claimed in claim 18, wherein said one or more
isoflavones are present in said composition in amount of from
0.00001 to 0.1% by weight.
21. A composition as claimed in claim 19, wherein said one or more
natural extract containing said one or more isoflavones are present
in said composition in amount of from 0.00001 to 0.1% by weight.
22. A cosmetic composition as claimed in claim 1, said composition
further comprising a cosmetically-acceptable vehicle.
23. A composition as claimed in claim 1, wherein said composition
further comprises liposomes.
24. A composition as claimed in claim 23, wherein said composition
comprises glycerol dilaurate, cholesterol, polyoxyethylene-10-
stearyl ether and polyoxyethylene-9-lauryl ether.
25. A composition as claimed in claim 1, wherein said composition
comprises from 1 to 99% bean milk, from 0.1 to 20% emulsifier
and preservatives in an effective amount.
26. A composition as claimed in claim 1, wherein said composition
comprises from 0.5 to 20% soybean powder or soymilk powder,
from 0.1 to 20% emulsifier and preservatives in an effective
amount.
27. A composition as claimed in claim 25, wherein said composition
further comprises one or more isoflavones in an amount of from
0.00001 to 0.1%.
28. A composition as claimed in claim 25, wherein said composition
further comprises one or more natural extracts comprising one or
more isoflavons in an amount of from 0.0001 to 0.1%.
29. A composition as claimed in claim 1, wherein said composition
further comprises one or more isoflavones in an amount of from
0.0001 to 0.1%.
30. A composition as claimed in claim 26, wherein said composition
further comprises one or more natural extracts comprising one or
more isoflavones in an amount of from 0.0005 to 0.05%.
A composition for affecting changes in mammalian hair growth, hair
pigmentation and hair shaft and follicle size, comprising topically
applying to skin of a mammal an effective amount of a topically active
composition comprising one or more compounds derived from one or
more of the botanical families leguminosae, solanaceae, gramineae and
cucurbitaceae.

Documents:

00424-cal-2000-abstract.pdf

00424-cal-2000-claims.pdf

00424-cal-2000-correspondence.pdf

00424-cal-2000-description (complete).pdf

00424-cal-2000-drawings.pdf

00424-cal-2000-form 1.pdf

00424-cal-2000-form 18.pdf

00424-cal-2000-form 2.pdf

00424-cal-2000-form 26.pdf

00424-cal-2000-form 3.pdf

00424-cal-2000-form 5.pdf

00424-cal-2000-letter patent.pdf

00424-cal-2000-priority document.pdf

00424-cal-2000-reply f.e.r.pdf

« Previous Patent

Next Patent »

Patent Number

216345

Indian Patent Application Number

424/CAL/2000

PG Journal Number

11/2008

Publication Date

14-Mar-2008

Grant Date

12-Mar-2008

Date of Filing

26-Jul-2000

Name of Patentee

JOHNSON & JOHNSON CONSUMER COMPANIES INC.,

Applicant Address

GRNDVIEW ROAD, SKILLMAN, NEW JERSEY 08558, A NEW JHERSEY CORPORATION USA.

Inventors:

#	Inventor's Name	Inventor's Address
1	SEOBERG MIRI,	168 HERRONTOWN ROAD, PRINCETON NJ 08540, USA.
2	SHAPIRO STANLEY S.	10, PLYMOUTHY DRIVE, LIVINGSTON NJ 07039 USA.
3	LIU JUE-CHEN,	268, BERKLEYU AVENUE, BELLE MEAD NJ08502 USA.
4	MILLER JONATHAN	2701 JUNTERS GLEN DRIVE PLAINSBORO, NJ-08536 USA.

PCT International Classification Number

D04B 15/48

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	60/145,774	1999-07-27	U.S.A.